# An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

> **NCT05884255** · PHASE3 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 220 (estimated)

## Conditions studied

- Advanced Gastroenteropancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
- **DRUG:** long-acting Octreotide

## Key facts

- **NCT ID:** NCT05884255
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2026-12
- **Final completion:** 2030-10
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05884255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05884255, "An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05884255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*